Sanofi presents new vaccine research at IDWeek 2021

Sanofi presented new research findings related to its vaccine pipeline at the IDWeek 2021 virtual congress in late September 2021. The studies featured focused on respiratory syncytial virus (RSV), meningococcal disease, and influenza, underscoring the company's commitment to advancing public health.

The congress included presentations on nirsevimab, a long-acting antibody developed jointly by Sanofi and AstraZeneca, aimed at preventing lower respiratory tract infections caused by RSV in infants. RSV is a common and serious virus that causes respiratory illnesses in infants, including bronchiolitis and pneumonia. Research highlighted that even healthy infants face a significant risk of hospitalization due to RSV.

In the segment on meningococcal disease, the company's vaccine, MenQuadfi, was discussed. This vaccine is designed to prevent diseases caused by serotypes A, C, Y, and W and is available in the U.S. for individuals aged two and older. The presented data assessed the long-term effects and safety of the vaccine across various age groups, including booster doses for adults and adolescents over 59 years of age.

Sanofi emphasized its continued investment in vaccine development to reduce the burden of infectious diseases globally. The presentations at IDWeek aim to support the company's goal of providing solutions to protect human health throughout all stages of life, particularly for diseases with significant unmet needs.